GR Semicolon EN

Show simple item record

dc.contributor.author
Banika, Virginia
en
dc.date.accessioned
2016-01-19T07:48:14Z
dc.date.available
2016-01-20T01:00:21Z
dc.date.issued
2016-01-19
dc.identifier.uri
https://repository.ihu.edu.gr//xmlui/handle/11544/12423
dc.rights
Default License
dc.subject
Pharmaceutical
en
dc.subject
Respiratory
en
dc.subject
Generic
en
dc.subject
Consultancy
en
dc.title
The creation of a Contract Research pharmaceutical company focused on res-piratory disorders.
en
heal.type
masterThesis
el
heal.keywordURI.LCSH
Pharmaceutical industry
heal.keywordURI.LCSH
Pharmaceutical industry--Case studies
heal.keywordURI.LCSH
Pharmaceutical industry--Economic aspects
heal.keywordURI.LCSH
Pharmaceutical industry--Management
heal.keywordURI.LCSH
Pharmaceutical industry--Quality control
heal.keywordURI.LCSH
Drugs--Generic substitution
heal.language
en
el
heal.access
free
el
heal.license
http://creativecommons.org/licenses/by-nc/4.0
el
heal.references
Allied Market Research, World COPD and Asthma Devices Market - Opportunities and Fore casts 2013 – 2020 , 2013. Bloomberg 1 , Le a ding respiratory brands in 2018, 2015. Bloomberg 2 , To fix Greece debt woes, Generics are just what Doctors o r der, 2015. DataMonitor, Respiratory annual update, 2015. EFPIA, Annual report 2014, www.efpia.eu . EAACI, Asthm a Atlas, European Academy of Allergy and Clinical Immunology, 2015. EGA, European Gene ric Medicines Association , Market Review, Share of Generic Market , 2011 . European Lung Foundation, Adult Asthma, www.europeanlu ng.org , 2015 . Fred R. David, Forest R. David, Strategic Management 15 th edition. Frenk, J. & Moon, S., Governance challenges in global health. New England Journal of Medicine, 368, 936 - 942, 2013. Friedli T., Kickuth M., Stienker F ., Thaler P. and Werani J ., Operational exce l lence in the pharma industry. ECV. Editio Cantor Verlag, Bad Schussenried Germany, pp17 - 29 , 2006 . Hellenic Statistical Authority, statistics on National Health Expenditures (both public and private) based on the System of Health Account s (SHA) of the Organization for Economic Cooperation and Development (OECD), 2012. Hellenic Republic, S tate B udget E xecusion , final report, 2014. Elpen Pharma, 50 years "We insist on Greece. We remain in Greece , Press release, 2015. ΕSYΝΕΤ, Budget Execution Bulletins - Ministry of Finance, Mid - term Fiscal Strategy Framework 2015 - 2018, data processing IOBE, 2013. - 2 - FDA, Gudieline for Abbreviated New Drug Application (ANDA): Generics , www.fda.gov , 2015. Foundation for Economic & Industrial Research (IOBE) , Strategy Development for the Pharmaceutical sector , 2014. Global initiative for chronic Obstructive Lung Disease , Gudieline, 2015. Institute for Health Metrics and Evaluation , annual report, 2010. IMS H ealth, Yearlz report on respiratory portfolio, 2014. King A., Greek crisis puts pressure on pharmaceuticals, Chemistry world, 2015. Myasthma, Chiesei Pharma, www.myasthma.gr , 2015. Natz A., Pharmaceutical pricing: Imp act of the Greek pricing decisions on other Member States and the Transparency Directive , 2012 . OECD 1 , Aging debate the issues, 2015. OECD 2 , Health Statistics, 2015. Pneumologist, List of inhalation therapies in Greece, www. Pneumologist.gr, 2015. SFEE, 20 13, The pharmaceutical market in Greece Facts and Figures 2013. Skaltsas LN. and Vasileiou KZ., Patients perception of generic drugs in Greece , Health Policy 119(11):1406 - 14, 2015. Tzanakis N . , Anagnostopoulou U . , Filaditaki V . , Christaki P . and Siafakas N . , Prev a- lence of COPD in Greece , 2004 . Visiongain, World respiratory disorder market2009 - 2024, 2009. Volger S., The impact of pharmaceutical Pricing and Reimbursement Policies on G e- neric Uptake: Implementation of Policy options on Generics in 29 European cou n- tries - An overview’, Generics and Biosimilars Initiative Journal Vol1, No 2, pp 44 - 51 , 2012 . WHO, Respiratory disorders summary report, 2011. - 3 - WHO 1 , Access to new medicines in Europe: technical review of policy initiatives and opportunities for collabora tion and research, 2015. WHO 2 , Generic drugs review, 2015 . Yfantopoulos J., Pharmaceutical pricing and reimbursement reforms in Greece, Eur J Health Econ, 2007
el
heal.recordProvider
School of Economics, Business Administration and Legal Studies, Executive MBA
el
heal.publicationDate
2016-01-15
heal.tableOfContents
Contents ABSTRACT ................................ ................................ ................................ ............... IV PREFACE ................................ ................................ ................................ ................... I CONTENTS ................................ ................................ ................................ .............. III 1. INTRODUCTION ................................ ................................ ................................ .... 1 2. CHALLENGES THAT T HE PHARMACEUTICAL IN DUSTRY IS FACING .......................... 1 2.1 S USTAINABILITY OF THE HEALTH SYSTEM ................................ ................................ .......... 1 2.2 P ROFIT MARGINS ................................ ................................ ................................ ........ 2 2.3 P RICING OF MEDICINAL PRODUCTS ................................ ................................ ................. 2 2.4 P ATIENT ACCESS ................................ ................................ ................................ ......... 3 3. METHODS ................................ ................................ ................................ ............ 3 3.1 I NTERVIEWS WITH STAKE HOLDERS ................................ ................................ .................. 3 4. SELECTION OF THE DISEASE AREA ................................ ................................ ......... 5 4.1 I NTRODUCTION ................................ ................................ ................................ .......... 5 4.2 T HE MOST COMMON RESPI RATORY DISEASES ................................ ................................ .... 6 4.2.1 A STHMA ................................ ................................ ................................ ................ 6 4.2.2 C HRONIC O BSTRUCTIVE P ULMONARY D ISEASE (COPD) ................................ .................. 7 5. MARKET ANALYSIS ................................ ................................ ............................... 9 5.1 G EOGRAPHICAL BREAKDOW N OF THE RESPIRATORY MARKET ................................ ................ 9 5.2 T HE PHARMACEUTICAL CO MPANIES WORKING IN T HE RESPIRATORY AREA ............................. 10 5.3 R ESPIRATORY MARKET IN G REECE ................................ ................................ ................ 10 5.4 T HE GENERIC MARKET ................................ ................................ ............................... 11 - iv - 5.4.1 W ORLDWIDE USE OF GENE RICS ................................ ................................ ................ 11 5.4.2 G ENERICS IN G REECE ................................ ................................ ............................. 12 5.4.3 P ATIENTS ’ PERCEPTION OF GENERI C PRODUCTS ................................ ............................ 13 6. BUSINESS P LAN ................................ ................................ ................................ .. 14 6.1 B USINESS OBJECTIVES ................................ ................................ ................................ 14 6.1.1 V ISION ................................ ................................ ................................ ................ 14 6.1.2 M ISSION ................................ ................................ ................................ .............. 15 6.1.3 G OALS ................................ ................................ ................................ ................ 15 6.2 B USINESS STRATEGY ................................ ................................ ................................ .. 15 6.2.1 P HASE 1 ................................ ................................ ................................ .............. 16 6.2.2 P HASE 2 ................................ ................................ ................................ .............. 16 6.2.3 P HASE 3 ................................ ................................ ................................ .............. 17 6.3 SWOT A NALYSIS ................................ ................................ ................................ ..... 17 6.4 S CHEDULING ................................ ................................ ................................ ............ 18 6.5 P ROJECT O RGANIZATIONAL P LAN ................................ ................................ ................ 19 6.6 G ROWTH STRATEGY OF T HE COMPANY ................................ ................................ .......... 20 6.7 C ONSTRAINTS ................................ ................................ ................................ .......... 21 7. FINANCIAL ANALYSI S ................................ ................................ .......................... 21 7.1 S H AREHOLDING OF P ANAKIA ................................ ................................ ....................... 22 7.1.2 F INANCIAL P LAN OF P HASE 1 ................................ ................................ ................... 23 7.1.3 F INANCIAL PLAN OF P HASE 2 ................................ ................................ ................... 24 7.2 F UNDING PLAN ................................ ................................ ................................ ........ 25 - v - 8. HIGH LEVEL RISK A NALYSIS ................................ ................................ ................. 26 8.1 R ISK FACTORS ................................ ................................ ................................ .......... 26 8.1.1 T ECHNICAL RISKS ................................ ................................ ................................ ... 26 8.1.2 P ARTNERSHIP ................................ ................................ ................................ ....... 26 8.1.3 R ESOURCE AVAILABILITY ................................ ................................ .......................... 27 8.1.4 R EGULATION ................................ ................................ ................................ ........ 27 8.1.5 P ROJECT MANAGEMENT / S TRATEGY ................................ ................................ .......... 27 8.1.6 L AUNCHING OF PRODUCTS ................................ ................................ ...................... 28 8.1.7 H IGH R&D COSTS / C OSTLY METHODS OF DRU G DEVELOPMENT ................................ ...... 28 8.1.8 E XTERNAL FACTORS ................................ ................................ ................................ 28 8.2 R ISK MANAGEMENT ................................ ................................ ................................ .. 29 8.2.1. R ISK MANAGEMENT OF PO TENTIAL THREATS ................................ .............................. 29 CONCLUSIONS ................................ ................................ ................................ ........ 32 BIBLIOGRAPHY ................................ ................................ ................................ ......... 1 APPENDIX ................................ ................................ ................................ ................ 4 A. T HE QUESTIONNAIRE OF THE INTERVIEWERS ................................ ................................ ....... 4 B. I NDIVIDUAL ANSWERS ................................ ................................ ................................ ... 4 1. A VGUI C HARALAMBOUS P H .D , H EAD OF B USINESS D EVELOPMENT AT ELPEN P HARMA , G REECE 4 2. D IMITRIS A LEXANDROPOULOS , N ATIONAL S ALES M ANAGER COPD, N OVARTIS P HARMA H ELLAS , G REECE ................................ ................................ ................................ .......................... 5 3. F ADI E SKANDAR , S ENIOR M ANAGER OF R ESPIRATORY PORTFOLIO , S K YEPHARMA AG, S WITZERLAND ................................ ................................ ................................ .................. 6 4. M R . J OSEPH F AM , P ROJECT M ANAGER OF THE G OLF COUNTRIES IN S ANOFI A VENTIS , UAE. ...... 6 - vi - 5. P ANOS S PYROU , B USINESS U NIT D IRECTOR OF A STRA Z ENECA , G REECE ................................ .. 7 C. S HARE OF GENERICS IN THE TOTAL PHARMACEUT ICAL MARKET , 2013 ( OR NEAREST YEAR ) .......... 8 D. C AUSES OF DEATHS IN G REECE ................................ ................................ ........................ 9 E. H EALTH EXPENDITURE AS A PERCENTAGE OF GDP (OECD COUNTRIES ) ................................ ... 9 F. S EGMENTATION OF THE G REEK PH ARMACEUTICAL MARKET ................................ ................. 10
en
heal.advisorName
Marco, Sampietro
en
heal.committeeMemberName
Georgios, Banias
en
heal.committeeMemberName
Charilaos, Achillas
en
heal.academicPublisher
IHU
en
heal.academicPublisherID
ihu
el
heal.numberOfPages
33
el


This item appears in the following Collection(s)

Show simple item record

Related Items